MDCPartners News
David Cocker’s Presentation at the 10th Annual SFE & Commercial Excellence Europe 2012
“This year’s SFE brought together some of Europe’s leading commercial innovators in the pharmaceutical space, including excellent keynotes and hard hitting presentations that removed the gloss and placed emphasis on the touch challenges facing Pharma today.
A couple of clear messages emerged:
• Dr. Marc Czarka’s talk on market access and the rapidly changing landscape where governments and patients are going to vet the value of new medicines reaching national markets places new emphasis on patient advocacy and their product perception.
• Emergence of the digi-rep from Roche’s Andreas Claus Kistner, the age of the iPad is upon us and printed material is giving way to apps and animation. But there is more. AstraZeneca’s Florent Edouard closing the complete electronic loop from web to rep, the concept of a seemleass corporate digital eco-system allowing reps to bring the most relevant information to their markets while at the same time gathering compliant feedback to the corporate classification. The traditional CRM concept is inadequate, too expensive and fails to deliver the needs of an evolving market.
• Actelion’s Christoph Schmidt highlighted the challenges in orphan drug specialty selling and precisely described the change in paradigm from primary to specialty care.
Congratulations to the eyeforpharma team, a dynamic and focused group of individuals working hard to bring a diverse and exciting program. For me the bar has been raised and I look forward to next year’s event. “
David J. Cocker
If you want to download a copy of David Cocker’s presentation, please click here.
David Cocker to present at SFE Europe, March 2012
27th – 29th March 2012 | Hotel Rey Juan Carlos I, Barcelona
“Public Disclosure: An Inconvenient Truth”
10th Anniversary SFE & Commercial Excellence Europe
On March 28th David Cocker will be speaking at the SFE Europe & Commercial Excellence 2012 conference in Barcelona in Track 3: Sell More: Engage all your new stakeholders.
Track 3 will concentrate on six sessions including,
- Evolving customers
- Influence HCPs, payers, advocates and patients
- Patient value
- Identification and tracking of KOLs
- Stakeholder Relationship Management
This conference will focus on the evolving needs of the customer through industry’s leading ideas. With over 1000 attendees, 9 tracks and 10 workshops, David will be presenting alongside 70 other handpicked speakers.
To download a copy of the program, please click here.
New normScan Version 3.1
We are happy to announce that we have added more information on the regulatory status of standards and that the graphical time evolution per standard now reflects the nationally adopted versions of international standards to normScan V.3.1.
normScan can now also indicate standards referenced by the FDA, and monitor these on a monthly basis alerting you by email to any changes.
For further insights, normScan also now offers three sub-tabs per standard; properties, attachments and the evolution.
If you would like to learn more about normScan and how it can help you monitor standards, please click here or contact us directly at .(JavaScript must be enabled to view this email address).
MDCPartners would like to introduce two new members of their expanding team
MDCPartners is constantly working on ideas to improve both ta-Scan and normScan as both business and regulatory intelligence tools. As such, we are pleased to announce two new members of our team to help us with our continued improvement efforts:
Joke Lievens, PhD
Business Consultant
Joke initially trained as a research scientist at the KULeuven Center for Molecular and Vascular Biology, where she completed a thesis on the development of HDL-cholesterol raising gene therapies for cardiovascular diseases. After obtaining her PhD, she held positions in the biopharmaceutical industry and academia in Belgium and France.
For INSERM/GIS Institut des maladies rares she has managed a large EU project on rare diseases and worked on the integration of next generation DNA sequencing in rare diseases research.
In the biopharmaceutical industry she has been involved in the development of targeted therapies for cancer. She held responsibility and developed operational expertise in the management of intellectual property portfolios and the search and evaluation of licensing opportunities for oncology drugs.
Besides her PhD in medical sciences, Joke holds a masters degree in bioengineering and is preparing a post-graduate degree in pharmaceutical medicine.
She is fluent in English, French and Dutch.
Jorge Saint-Aubyn, MSc
IT Project Manager
Jorge’s scientific background can be explained with his degree in Applied Mathematics from Simon Bolivar University (USB Venezuela) with courses in statistics from Lund University (Sweden).
In addition he obtained a MSc Degree in Operations Research from Maastricht University (The Netherlands) with courses in Machine Learning and Text Mining.
Along his career, he successfully completed assorted research in the fields of data analysis, IT industry and bioinformatics. For Zi-Decuma, Lund he trained as a researcher on a project implementing statistical methods to improve the clarity of handwriting on electronic tablets. He worked for CESMA (Statistics and Mathematical Software Center) at USB reviewing the implementions of Bayesian Kriging interpolation applied to produce digital maps of monthly rainfall for Venezuela and prepared the data input.
During his Master Thesis research, he investigated cardiac proteins and miRNA interactions that affect cardiac diseases using bioinformatics tools in collaboration with the Cardiology Department at Maastricht University. His interests rely mainly in the power of data visualization and information discovering.
He speaks Spanish, English and French.
Press Release - ta-Scan version 3.5 released
Introducing ta-Scan Version 3.5, a semantically driven business intelligence system.
Version 3.5 has a number of very important system enhancements:
• Capture new data such as healthcare professional’s payments
• Complete FDA site inspection data
• Aggregated information on 6,000 EMA medical and scientific experts
• 600,000 research organizations assessed by academic and clinical research pedigree, therapeutic expertise and experience with 14,000 drug classes
• 172 countries assessed for clinical research potential
• 2.6 million healthcare professionals ranked and profiled
Conclusions of DIA Clinical Forum and Presentation Download
“This DIA event was, in my opinion, extremely successful. The DIA departed from the usual themed track approach and created dynamic cross-functional themes which had interesting breakout sessions and expert debates. The standing of the speakers and the delivered content was truly on the mark and participants received expert tips on many industry challenges.
A couple of clear messages emerged from this year’s Clinical Forum:
• The need to realign public trust in the clinical research process. Over 75% of participants voted that our clinical research customers have lost faith in our processes. Trust needs to be rebuilt.
• Patient recruitment still plagues successful trial fulfillment. No real new ideas emerging and social media still seems an evolving strategy, though still awaiting regulatory direction.
• Emerging territories, while offering exceptional commercial potential, clinical research operations are continuing to be challenging and regulatory changes which frustrate many new study initiatives.
• Interestingly, many speakers alluded to the fact that complex and novel clinical research is moving towards the CRO sector. Some conclusions drawn could be that many major companies are mitigating risk by placing projects with experienced CROs when projects fall outside their traditional therapeutic comfort zone.
• Data standardization and electronic healthcare records still seem to be a thorny issue between the US and EU regulatory philosophies. Very much a question of ‘watch this space’.
• More surprisingly there seems to be a developing consensus by the FDA and EMA that the clinical trial process has become too arduous for our investigators. The talk is positive to expedite regulatory processes, though the hard endpoints are a little more elusive.
In general the meeting was multi-disciplinary and cross-functional. Probably one of the better DIA events that I have attended. Secondly, the DIA are attempting to get closer to the patient advocacy groups, who I must say, didn’t pull their punches describing Pharma’s seemingly antiquated clinical trial model. The quote of the conference was “perfect health is just an incomplete diagnosis” from the President of the Alzheimer’s Association.”
David J. Cocker
If you want to download David Cocker’s presentation, please .(JavaScript must be enabled to view this email address).
ta-Scan News Brief
In 2011 we consolidated many exciting features of ta-Scan business intelligence system. The public activation of the EMA, EudraCT trial registry and multiple corporate websites disclosing data has enriched outreach, widened data depth and improved accuracy. But we are not stopping here.
Our open market dialogue has always been the driving force behind our development policies and client feedback has helped shape many improvements that fit with our clients’ evolving business processes.
Major system changes
Significant changes in our robotic foundation will occur towards the end of the 2011. While we are comfortable that our concept provides a sustainable value proposition to our clients, we strive to continually improve the depth and quality of the data.
ta-Scan has always provided a timely snap shot of the worldwide Pharma development space. However, data refreshes always overwrote the previous version. As of October 2011 we will launch DeltaCheck 1.0. This release will time stamp all changes in captured web information. DeltaCheck 1.0 will offer many new advanced algorithms and visualizations. This technology enhancement will benefit our users:
• Monthly update cycle
• Evolution monitoring (a new colour rendering system indicating date and data timeline)
• Enhanced meta-analysis, including trends in all our traditional data classes
• Custom GUI and email alerts
Site selection automation (The Wizards)
The terabytes of public data on the internet today rarely render one clear and faithful picture. However, through our intelligent meta-analysis techniques we expose trends, statistics and enable a user to test multiple planning scenarios based on evidence.
Indexing the indices
The challenge of many web resources is the ability to find what you are looking for. The better the index, the better the search result. ta-Scan has advanced indexing algorithms to pin point references in complex textual information. Whether looking for key words in trial inclusion criteria or novel biomarker, ta-Scan semantically links multiple websites to create a cluster of indices enabling more precise user search criteria.
‘The Future of Standardization’ by Mireille De Cré and John Brennan - now available online
‘The future of standardization in the context of the European medical device legal framework and regulatory globalization’
Mireille De Cré and John Brennan
The European legislation which governs medical devices is undergoing continual evolution and this article analyzes and highlights the importance of all stakeholders’ participation in standards development.
Please click here to view this article.
Please note that this article first appeared in the June 2011 issue (volume 3, number 3) of the Global Forum and that copyright to this article is held by the DIA.
ta-Scan Version 3.4 is now live
ListBuilder 2
We are delighted to introduce the ListBuilder module –accessible from the homepage-, which makes it straightforward to build lists of medical experts, sites or trials based on your specific criteria. Your customized lists will extract data from the ta-Scan central database which has over 2 million individuals and 600,000 organizations. Through a user friendly wizard, you will be able to generate downloadable lists tuned to your needs. The ListBuilder is populated with over 20 useful presets enabling fast access to complex algorithms. We have built an easy to use graphic interface which compresses multifaceted parameters into a one simple graphic dialogue with the user. You can produce lists combining multiple indications and geographies, plot organizations or individuals by therapeutic experience and by time points.
Click here to see more information on ListBuilder 2
Expanded data sources
- Integration of European (EudraCT trial registry), expanding European trial resolution and sponsor activity
- New data sources have been introduced to the system:
Corporate healthcare payment lists
20,000 Healthcare professionals updated
Ancillary information in organization drilldown such as PET scanners - Organizations have now been classified to include CROs (Contract Research Organizations)
- New regional radar graphic for study setup time
- Undisclosed site details from trial registries have now been semantically inferred to identify sites based on factors such as literature and other internet footprint factors
Improved Search Indexes
The search indexes now incorporate a text sensitive search for inclusion and exclusion criteria fields in trial registries. This will enable a user to generate more specific trial lists.
MDCPartners attended the American Society of Clinical Oncology (ASCO) Annual Meeting 2011
David Cocker attended the American Society of Clinical Oncology (ASCO) Annual Meeting 2011 which was held in Chicago between June 3rd and 7th. This culminated in the release of ta-Scan V.3.4 which also includes an expanded oncology indication within the platform.
Click here for more information on ASCO.
ta-Scan releases ListBuilder module
Version 3.3 is now complemented by an extensive client side ListBuilder Wizard.
You can create custom lists in multiple indications and layer people and organisations connected to evidence of clinical research. The ListBuilder wizard has been specifically designed for user ease. A step-by-step wizard format takes you to individual preset queries which allows fast access to ta-Scan data. With this release is also an updated treatment of the Excel spreadsheet download format. For more information view the PDF data sheet
ta-Scan version 3.3 released!
What’s new in ta-Scan v3.3?
- Re-sculpted start page
- Extended help resources
- PubLink
- ListBuilder v.1
- Bookmark sharepoint
- Worldwide cluster data
Visit the ta-Scan product website
Events
37th ESMO Congress
28 September – 2 October 2012 | Vienna, Austria
Click here to view the preliminary programme.
2012 Bio International Convention
18 – 21 June 2012 | Boston, Massachusetts
Click here to view the programme.
ASCO Annual Meeting 2012
1 – 5 June 2012 | Chicago, Illinois
Click here to view preliminary session information.
2012 IMPAKT Breast Cancer Conference
3 – 5 May 2012 | Brussels, Belgium
Click here to view the preliminary programme.
24th Annual DIA Euromeeting
26 – 28 March 2012 | Copenhagen, Denmark
Click here to see the advanced programme.
Subscribe to the MDCPartners Newsletter
Sign up for our free quarterly newsletter which gives the latest information on our activities, products and market developments.
MDCPartners respects your privacy. You can unsubscribe anytime.